Tag Archives: Max Nisen

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

Germany’s Merck puts consumer drugs business up for sale; does this signal a last-ditch shot at M&A or just shoring up existing pipeline?

The News: Merck KGaA (Darmstadt DEU) put its consumer-health unit on the block Tuesday (September 5, 2017) in a move that will focus its healthcare activities on the riskier business… Read more »

UnitedHealthcare 2nd quarter sparkles; but time to figure out how Centene, Molina exploit Medicaid?

The News: UnitedHealth Group Inc.’s (Minnetonka MN) second-quarter earnings jumped 11% to beat analysts’ expectations even though the nation’s largest health insurer took a bigger hit than expected from coverage… Read more »

Trump’s rejoinder to Senate GOP: repeal Obamacare now, replace it later; or just forget the whole thing.

The News: US President Donald Trump urged Republican senators on Friday (June 30, 2017) to repeal Obamacare immediately if they cannot agree on a new healthcare plan to replace it,… Read more »

GOP Senate bill ignites massive rally in healthcare stocks; remember the dot-com era?

US healthcare stocks posted sharp gains last week, with pharma, hospitals and insurers climbing after Senate Republicans released a draft bill to scrap Obamacare, while a recent explosion in biotech… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety

The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

NIH proves immune to Trump’s budget scalpel

The News: Lawmakers expanded instead of slashed the budget for the National Institutes of Health (NIH) in its bipartisan deal to fund the government earlier this week, essentially snubbing the… Read more »